BofA Securities initiated coverage on Turning Point Therapeutics with a new price target
$TPTX
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities initiated coverage of Turning Point Therapeutics with a rating of Buy and set a new price target of $58.00